Reviewing Dyne Therapeutics (NASDAQ:DYN) & Opus Genetics (NASDAQ:IRD)

Dyne Therapeutics (NASDAQ:DYN) and Opus Genetics (NASDAQ:IRD) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, valuation, profitability, risk and dividends.

Risk and Volatility

Dyne Therapeutics has a beta of 1.07, meaning that its share price is 7% more volatile than the S&P 500. Comparatively, Opus Genetics has a beta of 0.59, meaning that its share price is 41% less volatile than the S&P 500.

Profitability

This table compares Dyne Therapeutics and Opus Genetics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-64.30%	-50.33%
Opus Genetics	-1,091.82%	-338.88%	-150.13%

Earnings and Valuation

This table compares Dyne Therapeutics and Opus Genetics”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21 million	($3.33)	-7.84
Opus Genetics	$14.20 million	23.57	-$49.59 million	($1.35)	-3.00

Opus Genetics has higher revenue and earnings than Dyne Therapeutics. Dyne Therapeutics is trading at a lower price-to-earnings ratio than Opus Genetics, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 15.0% of Opus Genetics shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 11.7% of Opus Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current ratings for Dyne Therapeutics and Opus Genetics, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1	2	10	2	2.87
Opus Genetics	1	1	15	1	2.89

Dyne Therapeutics currently has a consensus target price of $34.42, indicating a potential upside of 31.86%. Opus Genetics has a consensus target price of $10.69, indicating a potential upside of 164.01%. Given Opus Genetics’ stronger consensus rating and higher possible upside, analysts plainly believe Opus Genetics is more favorable than Dyne Therapeutics.

Summary

Opus Genetics beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

About Dyne Therapeutics

Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.

About Opus Genetics

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.